Pan-AKT抑制剂Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌:随机、安慰剂对照II期试验(ProCAID)
PURPOSE: Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS AND METHODS: ProCAID was a placebo controlled randomized phase II trial in mCRPC.…
要点
- Capivasertib联合多西他赛未显著改善mCRPC的复合无进展生存期(cPFS)。
- cPFS和OS结果与PI3K/AKT/PTEN通路激活状态无关。
核心结论
- 在mCRPC患者中,capivasertib联合多西他赛和泼尼松龙未能延长复合无进展生存期(cPFS),无论PI3K/AKT/PTEN通路激活状态如何。
- 观察到的总生存期(OS)获益为次要终点,需未来前瞻性研究验证以排除偏倚。
研究设计与样本
- 随机化采用最小化因素:骨转移、内脏转移、研究站点、既往阿比特龙或恩扎卢胺治疗。
主要发现
- cPFS和OS结果与PI3K/AKT/PTEN通路激活状态无关。
- 3-4级不良事件发生率两组相同(62.2%);capivasertib相关最常见任何级别不良事件为腹泻、疲劳、恶心和皮疹。
临床怎么用
- 对于mCRPC患者,不推荐在化疗基础上常规联合capivasertib以改善cPFS。
- 总生存期获益为次要终点,需进一步前瞻性验证后方可考虑临床使用。
局限性
- 总生存期(OS)为次要终点,结果可能受偏倚影响,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS AND METHODS: ProCAID was a placebo controlled randomized phase II trial in mCRPC. Patients received up to ten 21-day cycles of docetaxel (75 mg/m2 intravenous, day 1) and prednisolone (5 mg twice daily, oral, day 1-21) and were randomly assigned (1:1) to oral capivasertib (320 mg twice daily, 4 days on/3 days off, from day 2 each cycle), or placebo, until disease progression. Treatment allocation used minimization factors: bone metastases; visceral metastases; investigational site; and prior abiraterone or enzalutamide. The primary objective, by intention to treat, determined if the addition of capivasertib prolonged a composite progression-free survival (cPFS) end point that included prostate-specific antigen progression events. cPFS and overall survival (OS) were also assessed by composite biomarker subgroup for PI3K/AKT/PTEN pathway activation status. RESULTS: One hundred and fifty patients were enrolled. Median cPFS was 7.03 (95% CI, 6.28 to 8.25) and 6.70 months (95% CI, 5.52 to 7.36) with capivasertib and placebo respectively (hazard ratio [HR], 0.92; 80% CI, 0.73 to 1.16; one-sided P = .32). Median OS was 31.15 (95% CI, 20.07 to not reached) and 20.27 months (95% CI, 17.51 to 24.18), respectively (HR, 0.54; 95% CI, 0.34 to 0.88; two-sided P = .01). cPFS and OS results were consistent irrespective of PI3K/AKT/PTEN pathway activation status. Grade III-IV adverse events were equivalent between arms (62.2%). The most common adverse events of any grade deemed related to capivasertib were diarrhea, fatigue, nausea, and rash. CONCLUSION: The addition of capivasertib to chemotherapy did not extend cPFS in mCRPC irrespective of PI3K/AKT/PTEN pathway activation status. The observed OS result (a secondary end point) will require prospective validation in future studies to address potential for bias.
引用
- Crabb SJ, Griffiths G, Marwood E, et al. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). J Clin Oncol. 2020. PMID: 33326257. doi:10.1200/JCO.20.01576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。